Literature DB >> 27352265

Bladder Cancer and Genetic Mutations.

Xiaoying Zhang1, Yangde Zhang2.   

Abstract

The most common type of urinary bladder cancer is called as transitional cell carcinoma. The major risk factors for bladder cancer are environmental, tobacco smoking, exposure to toxic industrial chemicals and gases, bladder inflammation due to microbial and parasitic infections, as well as some adverse side-effects of medications. The genetic mutations in some chromosomal genes, such as FGFR3, RB1, HRAS, TP53, TSC1, and others, occur which form tumors in the urinary bladder. These genes play an important role in the regulation of cell division which prevents cells from dividing too quickly. The changes in the genes of human chromosome 9 are usually responsible for tumor in bladder cancer, but the genetic mutation of chromosome 22 can also result in bladder cancer. The identification of p53 gene mutation has been studied at NIH, Washington, DC, USA, in urine samples of bladder cancer patients. The invasive bladder cancers were determined for the presence of gene mutations on p53 suppressor gene. The 18 different bladder tumors were evaluated, and 11 (61 %) had genetic mutations of p53 gene. The bladder cancer studies have suggested that 70 % of bladder cancers involve a specific mutation in a particular gene, namely telomerase reverse transcriptase (TERT) gene. The TERT gene is involved in DNA protection, cellular aging processes, and cancer. The Urothelial carcinomas of the bladder have been described in Atlas of genetics and cytogenetics in oncology and hematology. HRAS is a proto-oncogene and has potential to cause cancer in several organs including the bladder. The TSC1 c. 1907 1908 del (E636fs) mutation in bladder cancer suggests that the location of the mutation is Exon 15 with frequency of TSC1 mutation of 11.7 %. The recent findings of BAP1 mutations have shown that it contributes to BRCA pathway alterations in bladder cancer. The discoveries of more gene mutations and new biomarkers and polymerase chain reaction bioassays for gene mutations in bladder cancer need further research.

Entities:  

Keywords:  Bladder cancer; Gene mutation; Oncogene; Telomerase reverse transcriptase gene

Mesh:

Substances:

Year:  2015        PMID: 27352265     DOI: 10.1007/s12013-015-0574-z

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  25 in total

1.  Downregulation of topoisomerase 1 and 2 with acriflavine sensitizes bladder cancer cells to cisplatin-based chemotherapy.

Authors:  Parisa Zargar; Shabnaz Koochakkhani; Marziyeh Hassanzadeh; Yaghoub Ashouri Taziani; Hamid Nasrollahi; Ebrahim Eftekhar
Journal:  Mol Biol Rep       Date:  2022-01-28       Impact factor: 2.316

Review 2.  Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives.

Authors:  Sen Liu; Xu Chen; Tianxin Lin
Journal:  J Adv Res       Date:  2021-11-24       Impact factor: 12.822

3.  Genome-wide mutation profiling and related risk signature for prognosis of papillary renal cell carcinoma.

Authors:  Chuanjie Zhang; Yuxiao Zheng; Xiao Li; Xin Hu; Feng Qi; Jun Luo
Journal:  Ann Transl Med       Date:  2019-09

4.  Identification and Validation of SNP-Containing Genes With Prognostic Value in Gastric Cancer via Integrated Bioinformatics Analysis.

Authors:  Hui Li; Jing Guo; Guang Cheng; Yucheng Wei; Shihai Liu; Yaoyue Qi; Gongjun Wang; Ruoxi Xiao; Weiwei Qi; Wensheng Qiu
Journal:  Front Oncol       Date:  2021-04-27       Impact factor: 6.244

Review 5.  The Interplay between Oxidative Stress, Inflammation and Angiogenesis in Bladder Cancer Development.

Authors:  Paulina Wigner; Radosław Grębowski; Michał Bijak; Joanna Saluk-Bijak; Janusz Szemraj
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

6.  Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer.

Authors:  Luca Falzone; Saverio Candido; Rossella Salemi; Maria S Basile; Aurora Scalisi; James A McCubrey; Francesco Torino; Salvatore S Signorelli; Maurizio Montella; Massimo Libra
Journal:  Oncotarget       Date:  2016-11-08

Review 7.  Immunological Approaches Towards Cancer and Inflammation: A Cross Talk.

Authors:  Xinglong Qu; Ying Tang; Shucheng Hua
Journal:  Front Immunol       Date:  2018-03-20       Impact factor: 7.561

Review 8.  Unmasking molecular profiles of bladder cancer.

Authors:  Xuan-Mei Piao; Young Joon Byun; Wun-Jae Kim; Jayoung Kim
Journal:  Investig Clin Urol       Date:  2018-02-01

9.  The Epithelial to Mesenchymal Transition Related Gene Calumenin Is an Adverse Prognostic Factor of Bladder Cancer Correlated With Tumor Microenvironment Remodeling, Gene Mutation, and Ferroptosis.

Authors:  YiHeng Du; WenHao Miao; Xiang Jiang; Jin Cao; Bo Wang; Yi Wang; Jiang Yu; XiZhi Wang; HaiTao Liu
Journal:  Front Oncol       Date:  2021-06-03       Impact factor: 6.244

10.  LncRNA XIST/miR-200c regulates the stemness properties and tumourigenicity of human bladder cancer stem cell-like cells.

Authors:  Ran Xu; Xuan Zhu; Fangzhi Chen; Changkun Huang; Kai Ai; Hongtao Wu; Lei Zhang; Xiaokun Zhao
Journal:  Cancer Cell Int       Date:  2018-03-20       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.